Appili Therapeutics: a David taking on the COVID-19 Goliath and other infectious diseases

Infectious disease drug development.
  • The COVID-19 pandemic might be on the downturn, but it will inevitably be followed by new viral variants along with other viruses and pathogens that are difficult to treat
  • Appili Therapeutics is at the forefront of the fight against infectious diseases with a mission to find solutions to life-threatening infections
  • The company has joined a global consortium of pharmaceutical, manufacturing, and distribution leaders to develop oral antiviral AVIGAN®/REEQONUS™ (Favipiravir) for COVID-19

“We are running a large international Phase 3 clinical trial for an oral antiviral for COVID-19.”
— Armand Balboni, MD, PhD, CEO, Appili Therapeutics Inc.

Beyond COVID19, drug-resistant bacteria and fungi continue to be a growing problem with few new solutions on the horizon. These emerging, re-emerging, and resistant diseases are undermining the antibiotics and antifungal drugs we’ve relied on for decades. For example, Candida auris, a highly drug resistant fungus that has a high mortality rate, was lurking in hospitals and nursing homes long before COVID-19 took up residence. It is a serious and growing threat.



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Market One

Market One

Canada’s leading marketing agency for public companies.